Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 1 Completed
50 enrolled
Epigenetic Reprogramming in Relapse/Refractory AML
Phase 1 Completed
37 enrolled 11 charts
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
Phase 1 Completed
21 enrolled 12 charts
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Phase 1 Completed
17 enrolled 8 charts
MIBG With Dinutuximab +/- Vorinostat
Phase 1 Completed
45 enrolled 16 charts
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
Phase 1 Completed
18 enrolled
PRAVO
Phase 1 Completed
15 enrolled
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Phase 1 Completed
27 enrolled
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
Phase 1 Completed
72 enrolled
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Phase 1 Completed
23 enrolled
MK-0683-029
Phase 1 Completed
18 enrolled 24 charts
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Phase 1 Completed
68 enrolled
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
Phase 1 Completed
33 enrolled
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Phase 1 Completed
70 enrolled
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
Phase 1 Completed
30 enrolled
MK-0683-098
Phase 1 Completed
9 enrolled 9 charts
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Phase 1 Completed
143 enrolled
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
16 enrolled 7 charts
SAHA
Phase 1 Completed
40 enrolled 13 charts
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Phase 1 Completed
17 enrolled 5 charts
MK-0683-074
Phase 1 Completed
31 enrolled 13 charts
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 1 Completed
19 enrolled
NSCLC
Phase 1 Completed
18 enrolled
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
56 enrolled
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Phase 1 Completed
27 enrolled
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Phase 1 Completed
7 enrolled
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Phase 1 Completed
22 enrolled
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Phase 1 Completed
17 enrolled
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
Phase 1 Completed
17 enrolled
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
17 enrolled
Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
Phase 1 Completed
152 enrolled
Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer
Phase 1 Completed
21 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
Phase 1 Completed
30 enrolled
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Phase 1 Completed
24 enrolled
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
Phase 1 Completed
61 enrolled 9 charts
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Phase 1 Completed
20 enrolled
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase 1 Completed
29 enrolled
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Phase 1 Completed
78 enrolled
A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)
Phase 1 Completed
10 enrolled
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Phase 1 Completed
71 enrolled 9 charts
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
Phase 1 Completed
25 enrolled 21 charts
Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
28 enrolled
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Phase 1 Completed
23 enrolled 7 charts
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Phase 1 Completed
21 enrolled
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Phase 1 Completed
34 enrolled 10 charts
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Phase 1 Completed
10 enrolled 11 charts
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Phase 1 Completed
15 enrolled
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
80 enrolled
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Completed
60 enrolled